

**Demographic and clinical characteristics of study participants**

<b>Characteristic</b>	<b>Group 1 N = 8,222</b>	<b>Group 2 N = 3,412</b>	<b>State N=143,057</b>	<b>p-value<sup>1</sup></b>
Age	Mean = 11.26 (SD = 3.89)	Mean = 10.60 (SD = 3.80)	Mean = 11.28 (SD = 3.91)	ns
Gender (Male)	59.20%	67.20%	61.40%	<.0001
Race/Ethnicity				<.0001
Caucasian	75.10%	67.50%	74.20%	
African American	20.40%	27.30%	21.40%	
Other <sup>2</sup>	4.52%	5.19%	4.47%	
Eligibility				<.0001
Low Income	80.70%	76.10%	84.10%	
Disabled	16.00%	18.90%	14.50%	
Foster	3.27%	5.10%	1.36%	
Primary Diagnosis				<.0001
Attention Deficit Hyperactivity	33.70%	39.80%	44.40%	
Adjustment	7.47%	6.25%	6.05%	
Autism	3.13%	3.49%	1.69%	
Bipolar	8.52%	10.30%	5.18%	
Anxiety	5.44%	3.52%	4.26%	
Conduct/Oppositional Defiant	4.03%	8.72%	3.89%	
Depression	11.00%	8.01%	7.53%	
Schizophrenia/Psychosis	2.67%	5.17%	3.01%	
Substance	0.84%	0.41%	0.38%	
Intellectual Disability	0.93%	0.76%	1.08%	
Psychiatric Comorbidities				<.0001
1	34.10%	35.10%	43.90%	
2 or more	55.20%	61.40%	40.60%	
Any Medical Comorbidities	23.70%	14.80%	16.60%	<.0001

<sup>1</sup>Based on one-way ANOVA for age and Pearson Chi-Square with Bonferroni correction for all remaining characteristics

<sup>2</sup>Asian, Pacific Islander, Hispanic, American Indian, Mutually Defined

### Change in prevalence of prescribing measures

Comparison Groups	Baseline Prevalence Rate (95% CI)	Follow-up Prevalence Rate (95% CI)	Rate Difference (95% CI)	% Δ	p-value
<b>Measure 1: AP Use Among Children Two through Five Years of Age</b>					
State (n=9,649)	13.06 (12.55 – 13.57)	11.58 (11.09 – 12.08)	-1.47 (-2.33 - -0.61)	-11.2	0.0017
Group 1(n=646)	9.83 (8.00 – 11.67)	9.88 (8.02 – 11.74)	0.05 (-3.11 – 3.20)	0.5	0.9283
Group 22 (n=277)	11.50 (7.64 – 15.37)	5.85 (3.48 – 8.21)	-5.65 (-11.0 - -0.35)	-49.1	0.0155
<b>Measure 2: AP Polypharmacy</b>					
State (n=27,521)	6.14 (5.95 – 6.32)	5.98 (5.79 – 6.46)	-0.16 (-0.47 – 0.15)	-2.6	0.4295
Wave 1 (n=2,130)	4.74 (4.09 – 5.39)	3.60 (3.07 – 4.13)	-1.13 (-2.14 - -0.12)	-23.8	0.0455
Wave 2 (n=1,170)	13.94 (12.37 – 15.51)	9.78 (8.59 – 10.98)	-4.15 (-6.49 - -1.82)	-29.8	0.0017
<b>Measure 3: Psychotropic Polypharmacy</b>					
State (n=143,057)	3.38 (3.32 – 3.44)	3.21 (3.15 – 3.26)	-0.17 (-0.27 - -0.08)	-5.0	0.0108
Wave 1 (n=8,222)	4.51 (4.23 – 4.79)	4.27 (4.01 – 4.53)	-0.24 (-0.71 – 0.22)	-5.3	0.4473
Wave 2 (n=3,412)	7.74 (7.11 – 8.38)	6.31 (5.80 – 6.83)	-1.43 (-2.40 - -0.46)	-18.5	0.0203